Frequency of JAK2V617F mutations in polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis (MF).
| . | JAK2V617F Detection Method . | PV: JAK2V617F Mutations (homozygotes) . | ET: JAK2V617F Mutations (homozygotes) . | MF: JAK2V617F Mutations (homozygotes) . |
|---|---|---|---|---|
| James et al2 | Sequencing | 89 (30) | 43 | 43 |
| Levine et al3 | Sequencing | 74 (25) | 32 (3) | 35 (9) |
| Kralovics et al4 | Sequencing | 65 (27) | 23 (3) | 57 (22) |
| Baxter et al5 | Sequencing/allele-specific PCR | 97 (26) | 57 (0) | 50 (19) |
| Jones et al6 | ARMS/pyrosequencing | 81 (33) | 41 (7) | 43 (29) |
| Levine et al9 | Allele-specific Taqman assay | 99 | 72 | 39 |
| . | JAK2V617F Detection Method . | PV: JAK2V617F Mutations (homozygotes) . | ET: JAK2V617F Mutations (homozygotes) . | MF: JAK2V617F Mutations (homozygotes) . |
|---|---|---|---|---|
| James et al2 | Sequencing | 89 (30) | 43 | 43 |
| Levine et al3 | Sequencing | 74 (25) | 32 (3) | 35 (9) |
| Kralovics et al4 | Sequencing | 65 (27) | 23 (3) | 57 (22) |
| Baxter et al5 | Sequencing/allele-specific PCR | 97 (26) | 57 (0) | 50 (19) |
| Jones et al6 | ARMS/pyrosequencing | 81 (33) | 41 (7) | 43 (29) |
| Levine et al9 | Allele-specific Taqman assay | 99 | 72 | 39 |